Compare Abbott Laboratories (ABT) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Sibanye Stillwater Ltd — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Sibanye Stillwater Ltd trades at $8.29 (market cap $5.98B). The key difference: Abbott Laboratories is far larger — about 27.9× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| ABT | SBSW | |
|---|---|---|
Market Cap | $166.94B | $5.98B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $21.12 |
52-Week Low | $82.57 | $7.27 |
Enterprise Value | $193.69B | $7.60B |
Dividend Yield | 2.63% | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Sibanye Stillwater (SBSW) trades at $8.52, down 4.91% today, with a bearish technical signal and negative earnings trends. The company reported a net loss of $7.30 billion in 2024, though revenue remains substantial at $112.13 billion. Recent news highlights operational improvements, including a surge in EBITDA and management's debt reduction targets, but profitability challenges persist.
The outlook is mixed: low valuation multiples suggest potential upside if operational turnaround succeeds, but negative margins and high debt pose significant risks. Analyst sentiment leans bullish with 42.86% buy ratings, yet recent earnings misses and cash flow volatility warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
